Tisdag 26 November | 05:50:37 Europe / Stockholm
Svenska | English

Västra Hamnen Market Focus

Prenumeration

Bioextrax: The American start-up cancels deal
2024-01-25 10:30:00
  • Limited effect on short-term earnings, higher perceived risk
  • Bioextrax signs MoU with Chematur Engineering
  • We have adjusted the fair value to SEK 7.60 (10.50) per share

In September 2023, an American start-up company extended the license agreement with Bioextrax regarding production of PHA. In January 2024, the American company had to terminate the contract due to financial issues. Hence, our model suggests a fair value of SEK 7.60 per share.

The initial research report is available here.

About Market Focus

The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.

This is a press release from Västra Hamnen Corporate Finance AB. 
Web: vhcorp.se
Twitter: @vhcorp_se (https://twitter.com/vhcorp_se)

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden